DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
First Investment: 2022
In some kinds of cancer cells, the genetic pathways that guide the normal process of development and differentiation are disrupted, leading to uncontrolled tumor growth. Auron gathers large multi-omic datasets documenting gene and protein expression in normal cells, and applies machine learning to identify the pathways that have been co-opted in tumor cells. Then it can target these hijacked pathways with new therapies to block tumor cell growth. The company can also identify cancer patients who are more likely to respond to specific therapies.
Explore Companies
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules
Visolis
Using synthetic biology to manufacture carbon-negative materials